Adaptive Immune Gene Signatures Correlate with Response to Flotetuzumab, a CD123 X CD3 Bispecific Dart® Molecule, in Patients with Relapsed/Refractory Acute Myeloid Leukemia

被引：12

作者：

Rutella, Sergio ^{[1
]}

Church, Sarah E. ^{[2
]}

Vadakekolathu, Jayakumar ^{[1
]}

Viboch, Elena ^{[2
]}

Sullivan, Amy H. ^{[2
]}

Hood, Tressa ^{[2
]}

Warren, Sarah E. ^{[2
]}

Cesano, Alessandra ^{[2
]}

La Motte-Mohs, Ross ^{[3
]}

Muth, John ^{[3
]}

Lelievre, Helene ^{[4
]}

Lowenberg, Bob ^{[5
]}

DiPersio, John F. ^{[6
]}

Davidson-Moncada, Jan K. ^{[3
]}

机构：

[1] Nottingham Trent Univ, John van Geest Canc Res Ctr, Nottingham, England

[2] NanoString Technol Inc, Seattle, WA USA

[3] MacroGenics Inc, Rockville, MD USA

[4] Servier, Ctr Rech Cancerol Marseille, Suresnes, France

[5] Erasmus Univ, Dept Hematol, Med Ctr, Rotterdam, Netherlands

[6] Washington Univ, Sch Med, Dept Internal Med, Div Oncol, St Louis, MO 63110 USA

来源：

BLOOD | 2018年 / 132卷

关键词：

D O I：

10.1182/blood-2018-99-111539

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

444

引用

页数：3

共 50 条

[21] Preliminary Results from a Phase 1 Study of APVO436, a Novel Anti-CD123 x Anti-CD3 Bispecific Molecule, in Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome
Watts, Justin M.
Lin, Tara
Wang, Eunice S.
Mims, Alice S.
Cull, Elizabeth H.
Patel, Prapti A.
Shami, Paul J.
Walter, Roland B.
Cogle, Christopher R.
Chenault, Ruth A.
Macpherson, Bret
Chunyk, Allison Given
McMahan, Catherine J.
Gross, Jane A.
Stromatt, Scott
BLOOD, 2020, 136
[22] Treatment of relapsed and refractory acute myeloid leukemia (MDS transformation) with CD123 chimeric antigen receptor T cell and literature review
Ning, Y.
Guo, X.
Ren, J.
EUROPEAN JOURNAL OF IMMUNOLOGY, 2019, 49 : 1729 - 1729
[23] Preliminary Translational Results from an Ongoing Phase 1 Study of Flotetuzumab, a CD123 x CD3 Dart®, in AML/MDS: Rationale for Combining Flotetuzumab and Anti-PD-1/PD-L1 Immunotherapies
Rettig, Michael P.
Godwin, John
Vey, Norbert
Fox, Bernard
Ballesteros-Merino, Carmen
Bifulco, Carlo B.
Li, Daner
Primo, Daniel
Ballesteros, Joan
Sun, Jichao
Lelievre, Helene
Baughman, Jan
La Motte-Mohs, Ross
Muth, John
Moore, Paul
Bonvini, Ezio
Wigginton, Jon
DiPersio, John F.
Davidson-Moncada, Jan
BLOOD, 2017, 130
[24] Ex-vivo exposure-response characterization of antitumor activity of anti CD123 X CD3 DuoBody in primary acute myeloid leukemia (AML) bone marrow samples
Singh, Indrajeet
Parab, Nikita
Syed, Khaja
Jiang, Xiling
Sun, Yu-Nien
Huang, Fei
Sasser, Kate
Kalota, Anna
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2017, 44 : S40 - S40
[25] Bifunctional PD-1 x αCD3 x αCD33 fusion protein reverses adaptive immune escape in acute myeloid leukemia
Herrmann, Monika
Krupka, Christina
Deiser, Katrin
Brauchle, Bettina
Marcinek, Anetta
Wagner, Ana Ogrinc
Rataj, Felicitas
Mocikat, Ralph
Metzeler, Klaus H.
Spiekermann, Karsten
Kobold, Sebastian
Fenn, Nadja C.
Hopfner, Karl-Peter
Subklewe, Marion
BLOOD, 2018, 132 (23) : 2484 - 2494
[26] Updated Results from a Phase 1 Study of APVO436, a Novel Bispecific Anti-CD123 x Anti-CD3 Adaptir T Molecule, in Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome
Watts, Justin
Maris, Michael
Lin, Tara L.
Patel, Prapti
Madanat, Yazan F.
Cogle, Christopher R.
Borthakur, Gautam
Huebner, Dirk
Khaskhely, Noor
Bonham, Lynn
Massaro, Monica
Taylor, Daphne
Taromino, Caroline
Mims, Alice S.
BLOOD, 2022, 140 : 6204 - 6205
[27] Pharmacodynamic Effects and Immune Correlates of Response to the CD20/CD3 Bispecific Antibody Mosunetuzumab in Relapsed or Refractory Non-Hodgkin Lymphoma
Hernandez, Genevive
Huw, Ling-Yuh
Belousov, Anton
Wilson, Deanna
Koeppen, Hartmut
McCord, Ron
Peng, Kun
Bartlett, Nancy L.
Budde, Lihua E.
Assouline, Sarit
Nastoupil, Loretta J.
Yoon, Dok Hyun
Matasar, Matthew J.
Bender, Brendan
Kwan, Antonia
Li, Chi-Chung
O'Hear, Carol
Yin, Shen
Wei, Michael C.
Adamkewicz, Joanne I.
BLOOD, 2019, 134
[28] A Clinical Phase 1B Study of the CD3xCD123 Bispecific Antibody APVO436 in Patients with Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Uckun, Fatih M.
Lin, Tara L.
Mims, Alice S.
Patel, Prapti
Lee, Cynthia
Shahidzadeh, Anoush
Shami, Paul J.
Cull, Elizabeth
Cogle, Christopher R.
Watts, Justin
CANCERS, 2021, 13 (16)
[29] Control of acute myeloid leukemia and generation of immune memory in vivo using AMV564, a bivalent bispecific CD33 x CD3 T cell engager
Eissenberg, Linda G.
Ritchey, Julie K.
Rettig, Michael P.
Patel, Dilan A.
Vij, Kiran
Gao, Feng
Smith, Victoria
Han, Tae H.
Dipersio, John F.
PLOS ONE, 2024, 19 (05):
[30] Dose Escalation of HLA-A2-WT1 CD3 T-Cell Bispecific Antibody in a Phase I Study in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
Hutchings, Martin
Montesinos, Pau
Santoro, Armando
Hou, Hsin-An
Martinez-Sanchez, Maria Pilar
Vives, Susana
Galimberti, Sara
Chen, Tsai-Yun
Frigeni, Marco
Garciaz, Sylvain
Salamero, Olga
Yeh, Su-Peng
Yee, Karen
Schnetzler, Gabriel
Barata, Teresa
Simon, Silke
Hinton, Heather
Korfi, Koorosh
Richard, Muriel
Keshelava, Nino
Subklewe, Marion
BLOOD, 2023, 142

← 1 2 3 4 5 →